Roles of Sirtuins in Cardiovascular Diseases: Mechanisms and Therapeutics

Yang-Nan Ding1,2, Hui-Yu Wang2,3, Xiao-Feng Chen4

  • 1Department of Laboratory Medicine, Zhengzhou Key Laboratory for In Vitro Diagnosis of Hypertensive Disorders of Pregnancy, The Third Affiliated Hospital of Zhengzhou University, China (Y.-N.D.).

Circulation Research
|February 27, 2025
PubMed

Insights

Sirtuins, enzymes linked to aging, are crucial in cardiovascular diseases (CVDs). Activating Sirtuins shows promise for preventing and treating CVDs, offering new therapeutic avenues.

Area of Science:

  • Biochemistry and Molecular Biology
  • Cardiovascular Research
  • Aging Biology

Background:

  • Cardiovascular diseases (CVDs) are a leading cause of mortality in aging populations.
  • Understanding the molecular mechanisms of CVDs is critical due to their complex etiology.
  • Sirtuins, a family of NAD+-dependent deacylases, are conserved across species and link aging to various diseases.

Purpose of the Study:

  • To provide a comprehensive review of Sirtuin functions in cardiovascular biology and CVDs.
  • To discuss the role of Sirtuin activation in mitigating age-related diseases, including CVDs.
  • To highlight recent advancements in Sirtuin-targeting pharmacological interventions for CVDs.

Main Methods:

  • Literature review of Sirtuin biology and its implications in cardiovascular health and disease.
  • Analysis of research on Sirtuin-activating compounds and NAD+ boosters.
  • Discussion of current challenges and future directions in Sirtuin-targeted CVD research.

Main Results:

  • Sirtuins play a significant role in physiological and pathological processes, including aging and stress response.
  • Abnormal Sirtuin expression is linked to aging-related diseases like CVDs.
  • Sirtuin activation has demonstrated efficacy in preclinical models of CVDs.

Conclusions:

  • Sirtuins are critical regulators of cardiovascular biology and are implicated in the pathogenesis of CVDs.
  • Sirtuin-activating compounds and NAD+ boosters represent promising therapeutic strategies for CVD prevention and treatment.
  • Further research is needed to address chemicobiological regulation and clinical translation of Sirtuin-targeted therapies for CVDs.

Related Concept Videos

Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.3K
Pathophysiology of Cardiac Performance01:29

Pathophysiology of Cardiac Performance

Typical heart performance is influenced by heart rate, rhythm, myocardial contraction, and metabolism or blood flow. The cardiac muscle exhibits distinct electrophysiological features, including pacemaker activity and calcium channel control, which play a vital role in the heart's response to various drugs. The autonomic nervous system, comprising the sympathetic and parasympathetic branches, regulates heart rate. Sympathetic activation increases heart rate, while parasympathetic activation...
509
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.0K
Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
695
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
41